ALGS - Aligos halts development of Hep B candidate on safety concerns

Clinical-stage biotech, Aligos Therapeutics (NASDAQ:ALGS) announced on Tuesday that the company decided to discontinue the development of its chronic hepatitis B (CHB) candidate, ALG-020572 after a trial subject experienced a serious adverse event (SAE). Dosing of the first cohort of the trial came to a halt after the patient showed a significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that led to a brief period of hospitalization. According to the company, three other subjects in the cohort also experienced potentially drug-related ALT increases. The symptoms and lab results are improving in all four participants, Aligos (ALGS) said. With the CHB study discontinued, the company plans to focus its R&D efforts on oral small-molecule preclinical development programs. The clinical setback for Aligos (ALGS) comes only a few months after its IPO last year.

For further details see:

Aligos halts development of Hep B candidate on safety concerns